FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313889731> ?p ?o ?g. }

• W4313889731 endingPage "45" @default.
• W4313889731 startingPage "36" @default.
• W4313889731 abstract "Objective. The advent of immunotherapy has significantly changed the treatment and management of patients with advanced non-small cell lung cancer (NSCLC). Prior to initiation of immunotherapy,evaluation of programmed death ligand 1 (PD-L1) expression is required. One factor that affects PD-L1 expression in NSCLC is the presence of oncogenic driver mutations; however, little data on itsassociation is available, especially in the Philippine setting. The study aims to determine the prevalence of PD-L1 expression and its association with driver mutations among patients with non-small cell lung cancer in a private tertiary care hospital in the Philippines.Methodology. The study was undertaken for a period of two years from July 2017-July 2019 at St. Luke’s Medical Center and included 446 NSCLC samples. PD-L1 was evaluated by immunohistochemistry using 22C3 anti-PD-L1 antibody clone, EnVision FLEX visualization system on Autostainer Link 48. Patient demographics and data on driver mutation testing were recorded. Statistical analysis was performed using logistic regression.Results. PD-L1 expression was observed in 273 (61.20%) of 446 cases, 119 (61.20%) of whichdemonstrated high PD-L1 expression while 154 (34.50%) had low PD-L1 expression. There was nosignificant association between PD-L1 expression and EGFR mutation, ALK mutation, age, and gender.For histologic type, high PD-L1 expression was significantly associated with adenocarcinoma and non-small cell carcinoma, NOS.Conclusion. The overall prevalence of PD-L1 expression in non-small cell lung carcinoma is 61.20%based on the cases included. Although we did not find an association between PD-L1 expression andEGFR and ALK mutation, our study observed that ALK-mutated NSCLCs have 4.7 odds of having highPD-L1 expression, however, a higher sample size is warranted to truly determine significant association. The outcome of this study may provide help in the stratification of patients and predict those who will benefit from immunotherapy." @default.
• W4313889731 created "2023-01-10" @default.
• W4313889731 creator A5001986633 @default.
• W4313889731 creator A5017961374 @default.
• W4313889731 creator A5056526819 @default.
• W4313889731 creator A5080829251 @default.
• W4313889731 date "2022-12-31" @default.
• W4313889731 modified "2023-09-25" @default.
• W4313889731 title "Programmed Death Ligand 1 (PD-L1) Expression and its Association with Driver Mutations among Patients with Non-Small Cell Lung Cancer in a Private Tertiary Care Setting" @default.
• W4313889731 doi "https://doi.org/10.21141/pjp.2022.17" @default.
• W4313889731 hasPublicationYear "2022" @default.
• W4313889731 type Work @default.
• W4313889731 citedByCount "0" @default.
• W4313889731 crossrefType "journal-article" @default.
• W4313889731 hasAuthorship W4313889731A5001986633 @default.
• W4313889731 hasAuthorship W4313889731A5017961374 @default.
• W4313889731 hasAuthorship W4313889731A5056526819 @default.
• W4313889731 hasAuthorship W4313889731A5080829251 @default.
• W4313889731 hasBestOaLocation W43138897311 @default.
• W4313889731 hasConcept C104317684 @default.
• W4313889731 hasConcept C121608353 @default.
• W4313889731 hasConcept C126322002 @default.
• W4313889731 hasConcept C143998085 @default.
• W4313889731 hasConcept C151956035 @default.
• W4313889731 hasConcept C204232928 @default.
• W4313889731 hasConcept C2776256026 @default.
• W4313889731 hasConcept C2777701055 @default.
• W4313889731 hasConcept C2781053074 @default.
• W4313889731 hasConcept C2781182431 @default.
• W4313889731 hasConcept C501734568 @default.
• W4313889731 hasConcept C54355233 @default.
• W4313889731 hasConcept C71924100 @default.
• W4313889731 hasConcept C86803240 @default.
• W4313889731 hasConceptScore W4313889731C104317684 @default.
• W4313889731 hasConceptScore W4313889731C121608353 @default.
• W4313889731 hasConceptScore W4313889731C126322002 @default.
• W4313889731 hasConceptScore W4313889731C143998085 @default.
• W4313889731 hasConceptScore W4313889731C151956035 @default.
• W4313889731 hasConceptScore W4313889731C204232928 @default.
• W4313889731 hasConceptScore W4313889731C2776256026 @default.
• W4313889731 hasConceptScore W4313889731C2777701055 @default.
• W4313889731 hasConceptScore W4313889731C2781053074 @default.
• W4313889731 hasConceptScore W4313889731C2781182431 @default.
• W4313889731 hasConceptScore W4313889731C501734568 @default.
• W4313889731 hasConceptScore W4313889731C54355233 @default.
• W4313889731 hasConceptScore W4313889731C71924100 @default.
• W4313889731 hasConceptScore W4313889731C86803240 @default.
• W4313889731 hasIssue "2" @default.
• W4313889731 hasLocation W43138897311 @default.
• W4313889731 hasOpenAccess W4313889731 @default.
• W4313889731 hasPrimaryLocation W43138897311 @default.
• W4313889731 hasRelatedWork W1606053986 @default.
• W4313889731 hasRelatedWork W2374390921 @default.
• W4313889731 hasRelatedWork W2403361534 @default.
• W4313889731 hasRelatedWork W2792398055 @default.
• W4313889731 hasRelatedWork W3024255047 @default.
• W4313889731 hasRelatedWork W3117852629 @default.
• W4313889731 hasRelatedWork W3171615116 @default.
• W4313889731 hasRelatedWork W4200016977 @default.
• W4313889731 hasRelatedWork W4294406058 @default.
• W4313889731 hasRelatedWork W2553145634 @default.
• W4313889731 hasVolume "7" @default.
• W4313889731 isParatext "false" @default.
• W4313889731 isRetracted "false" @default.
• W4313889731 workType "article" @default.